Intercell AG

EANS-Adhoc: Intercell AG
Intercell AG Announces First Subject Enrolled in a Phase II Trial for the further development of its investigational Vaccine Enhancement Patch to improve Pandemic Influenza prevention in Collaboration with U.S. Department ...

-------------------------------------------------------------------------------- ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. -------------------------------------------------------------------------------- Research & Development 28.05.2009 » Phase II clinical trial investigating the effectiveness of Intercell´s Vaccine Enhancement (VE) Patch in combination with an injectable H5N1 pandemic influenza vaccine started today in the U.S. » The study is fully funded by HHS - this is the second study conducted under a 5 year USD 128 m contract with the HHS » Intercell´s VE Patch may reduce the dosage and improve protection against an H5N1 pandemic influenza outbreak with only a single dose vaccine application Vienna (Austria) and Gaithersburg (USA) May 28, 2009 - Intercell AG (VSE: ICLL) today announced that it has advanced its efforts to develop its VE Patch to improve prevention of H5N1 pandemic influenza with the start of a Phase II clinical trial. The randomized and blinded study aims to determine the optimal dosage of both Intercell´s VE Patch and the H5N1 influenza vaccine injected concomitantly, when combined with each other in a single dose regimen. The trial will be conducted in the U.S. and is expected to enroll 500 subjects at six study sites. "The commencement of this Phase II study represents an important milestone in the clinical development of our VE Patch technology and in the partnership with HHS for use of our technology in providing potentially improved Pandemic Influenza vaccines" stated Thomas Lingelbach, COO of Intercell AG and CEO of Intercell USA. "The recent H1N1 influenza situation certainly highlights again the important global public health need in this arena. If we achieve our goal to achieve full protection with only a single dose plus patch this means an enormous logistical advantage making PanFlu immunization feasible". The H5N1 pandemic influenza vaccine tested in the study comprises Intercell´s VE Patch and an injectable H5N1 influenza vaccine manufactured by Solvay Biologicals, B.V. (Netherlands). In 2008 Intercell announced the results of a first clinical trial where the VE Patch was combined with an injectable H5N1 influenza vaccine, also manufactured by Solvay Biologicals B.V. The data revealed that a single 45-microgram dose of the H5N1 influenza vaccine, when administered with the Intercell VE Patch containing 50-microgram LT adjuvant, was sufficient to provide an immune response seen to be protective in 73% of the vaccinees. This was a statistically significant improvement when compared to the subjects receiving the H5N1 influenza vaccine alone. Thus this was the first time that a single dose of H5N1 pandemic influenza vaccine met the level of protection suggested in U.S. Food and Drug Administration guidance that a pandemic vaccine needs to achieve immune response levels in at least 70% of the vaccine recipients in order to be considered protective. About Pandemic Influenza Three major influenza pandemics have occurred in the 20th century leading to the death of more than 50 million people globally. By U.S. government estimates, pandemic influenza has a greater potential to cause deaths and illnesses than virtually any other natural health threat. About Intercell´s Vaccine Enhancement Patch Intercell believes that its VE Patch when applied in conjunction with an injectable vaccine has the potential for the development of improved vaccine products. Preclinical studies with different vaccines and the Phase I/II clinical study results using the VE Patch with an injectable H5N1 Influenza vaccine suggest that this strategy may be used for other injectable vaccines which are already approved or in development where improved immunogenicity, decreased antigen doses, or fewer immunization visits are desired. end of announcement euro adhoc -------------------------------------------------------------------------------- ots Originaltext: Intercell AG Im Internet recherchierbar: http://www.presseportal.ch Further inquiry note: Intercell AG Lucia Malfent Head of Corporate Communications Tel. +43 1 20620-1303 lmalfent@intercell.com Branche: Biotechnology ISIN: AT0000612601 WKN: A0D8HW Index: ATX Prime, ATX Börsen: Wien / official market

Das könnte Sie auch interessieren: